Rocket Pharmaceuticals EBIT per Share

What does Rocket Pharmaceuticals do? Rocket Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and marketing gene therapies for rare diseases. The company was founded in 2015 as Inotek Pharmaceuticals Corp. and renamed Rocket Pharmaceuticals, Inc. in 2017. Rocket is headquartered in New York, USA, and operates various research and development sites as well as clinical development locations in Europe and the USA. The business model of Rocket Pharmaceuticals is based on identifying rare diseases for which there are currently limited or no treatment options. After identification, the company begins developing gene therapies that target the underlying genetic mutations and aim for a cure or symptom relief. Rocket Pharmaceuticals identifies rare diseases through collaboration with experts from various medical fields and seeks strategic partnerships with other research companies, universities, and government organizations. The company is divided into different divisions specializing in specific genomic areas. These include hemophilia, metabolic and cardiovascular diseases, as well as immunotherapy. Each division has a specialized team of scientists and researchers working on developing gene therapies for specific diseases. Within these different divisions, the company has developed or is in the process of developing a variety of products aimed at alleviating the symptoms of rare diseases and ultimately achieving a cure. Some of these products have already been approved for clinical research, while others are still in preclinical development. For example, the company has developed RP-L201, a gene therapy for Fanconi anemia, a rare genetic disorder that can cause severe blood diseases, malformations, and an increased risk of cancer. The therapy was approved by the US Food and Drug Administration (FDA) in 2019 and is now available for clinical trials in the US and Europe. Another example is RP-A501, a gene therapy for a severe form of methylmalonic acidemia (MMA), which is currently still in preclinical development. MMA is a rare inherited metabolic disorder that can lead to serious neurological and cardiovascular problems. Rocket Pharmaceuticals is also working on innovative therapies for other rare diseases such as LAD-1, a congenital immunodeficiency, or Danon disease, a rare inherited heart muscle disorder. In summary, Rocket Pharmaceuticals is a biopharmaceutical company focused on developing gene therapies for rare diseases. The company operates in different divisions and has developed a range of products aimed at alleviating the symptoms of rare diseases and achieving a cure. Its business model is based on identifying rare diseases and developing gene therapies targeting underlying genetic mutations. Rocket Pharmaceuticals collaborates closely with experts from various medical fields and seeks strategic partnerships with other research companies, universities, and government organizations. Rocket Pharmaceuticals is one of the most popular companies on Eulerpool.